Navigation Links
FDA Approves EDARBI (azilsartan medoxomil) for the Treatment of Hypertension
Date:2/25/2011

DEERFIELD, Ill. and OSAKA, Japan, Feb. 25, 2011 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., today announced that the U.S. Food and Drug Administration (FDA) approved EDARBI (azilsartan medoxomil) for the treatment of hypertension, or high blood pressure, in adults. EDARBI is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking the action of angiotensin II, a vasopressor hormone that constricts blood vessels. When the angiotensin II receptor is blocked, blood vessels stay relaxed and open and blood pressure can be reduced. EDARBI is approved as a once-daily oral therapy for use alone and for use in combination with other antihypertensive medications.

Takeda Global Research & Development Center, Inc. U.S. submitted a new drug application (NDA) for EDARBI in April 2010. The NDA was supported by seven controlled phase 3 clinical trials involving more than 5,900 patients with hypertension. Pivotal phase 3 studies showed EDARBI (80 mg/day) was statistically superior to placebo and the highest approved doses of two commonly prescribed ARBs, olmesartan medoxomil (40 mg/day) and valsartan (320 mg/day), in lowering both clinic and 24-hour mean blood pressure measurements.

"We are pleased to be able to build upon our global expertise in the cardiovascular therapeutic area with the approval of EDARBI in the U.S.," said Shinji Honda, president and CEO, Takeda Pharmaceuticals North America. "Through the discovery, development and commercialization of new medicines, Takeda is committed to bringing therapies like EDARBI to market. EDARBI is an important new treatment option for patients with hypertension and the health care professionals who treat them."

The safety and efficacy of EDARBI were studied as a once-daily oral therapy, as well as in combination with chlorthalidone and amlodipine. Results from the phase 3 clinical trials sh
'/>"/>

SOURCE Takeda Pharmaceuticals North America, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FDA Approves Product to Prevent Bleeding in People With Rare Genetic Defect
2. FDA Approves First 3-D Mammography Imaging System
3. FDA Approves 1st Pacemaker Designed to Work Safely During Some MRI Exams
4. FDA Approves Hologics Makena™ (Formerly Referred to as Gestiva™) Pharmaceutical
5. FDA Approves Drug to Reduce Risk of Preterm Birth in At-Risk Pregnant Women
6. FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth
7. FDA Approves Viibryd to Treat Major Depressive Disorder
8. FDA Approves Head Lice Treatment for Children and Adults
9. FDA Approves Opioid Analgesic to Help Cancer Patients Manage Pain
10. VIDEO from Endo Pharmaceuticals Available on thenewsmarket.com: FDA Approves New Treatment for Low Testosterone
11. FDA Approves New Dosage Strength for INTELENCE®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... 2015  Intec Pharma Ltd. (the "Company") (NASDAQ: ... developing drugs based on its proprietary Accordion Pill platform ... offering in the United States ... to the public of $6.00 per ordinary share, before ... are being offered by the Company.  In addition, the ...
(Date:8/4/2015)... , August 4, 2015 ... with market overview, trends, DRO analysis, market segmentation, ... competitive scenario and top competitor profiles in: ... Testing Market Development and Demand Forecast to 2020  ... Explore full reports with detailed TOC ...
(Date:8/4/2015)... -- Second Quarter 2015 Highlights: , ... of 2014 , Net earnings attributable to Team Health ... adjustments , Diluted net earnings per share of $0.39; ... to $99.4 million 2015 Outlook: , ... 24.0% to 26.0%; Adjusted EBITDA margin remains between 10.5% and ...
Breaking Medicine Technology:Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering 2Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering 3Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 2Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 3Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 4Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 5Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 2Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 3Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 4Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 5Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 6Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 7Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 8Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 9Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 10Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 11Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 12Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 13Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 14Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 15Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 16Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 17Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 18Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 19Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 20Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 21Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 22Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 23Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 24Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 25Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 26Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 27Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 28Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 29Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 30
... 2011 The grand opening ceremony for the world,s largest ... RNL BIO ( www.rnl.co.kr ), South Korea,s premier ... stem cell medical center in Beijing, China. Beijing RNL Stem ... Research Institute" (President : Li Hailing, www.yandaco.com ). Beijing ...
... harder to crush version of OxyContin® has a lower ... at a conference of law enforcement officers today. Last ... announced that every day 100 people die from drug ... pain relievers. A new formulation of the opioid pain ...
Cached Medicine Technology:RNL Opens the World's Largest Stem Cell Medical Center in Beijing, China 2New OxyContin® Has Lower Street Price Than Old Crushable Formulation 2
(Date:8/4/2015)... York, New York (PRWEB) , ... August 04, 2015 , ... ... this doesn’t begin to describe the customer experience inside Naimie’s Beauty Center in LA. ... help men learn how to look better. , Naimie’s Beauty Center has been a ...
(Date:8/4/2015)... ... August 04, 2015 , ... MedicaSoft ... Office of the National Coordinator for Health Information Technology (ONC-HIT) 2014 Edition ... highest quality personal health record and patient portal solution to healthcare providers ...
(Date:8/4/2015)... ... August 04, 2015 , ... Armadale ... finance, announced the closing of a $118 million FHA-insured loan modification refinancing for ... in Smithfield and Clayton, North Carolina. JHSC is a joint venture of ...
(Date:8/4/2015)... ... 04, 2015 , ... Half of consumers are considering a ... increasingly influential in their choice of practitioner, according to new survey data from ... Cosmetic Dermatologic Procedures reflects overall consumer views on cosmetic medical treatments and ratings ...
(Date:8/4/2015)... ... August 04, 2015 , ... Mercy Health (formerly Catholic Health Partners) – a Catholic ... Health: Helping You Be Well videos to preparing high school athletes for fall sports. , ... addresses issues, such as:, , What steps to take to help ...
Breaking Medicine News(10 mins):Health News:MENAJI Shines in Make-Up Mecca for Stars 2Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 2Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 3Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 2Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 3Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 2Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 3Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 4Health News:Mercy Health Video Provides Helpful Information for High School Athletes 2
... Preserving Choice, SACRAMENTO, Calif., Dec. 26 ... non-government HIV testing,program in California, today offered its ... into law yesterday in New Jersey by Acting ... testing of pregnant,women and some newborns for HIV, ...
... Inhibiting the growth of blood vessels that supply ... according to results of a large clinical trial ... in the December 27th issue of the New ... combination with chemotherapy significantly prolongs progression-free survival for ...
... to halting of cancer therapy, report says , , WEDNESDAY, ... for prostate cancer who take baby aspirin to protect ... new research suggests. , Apparently, baby aspirin interacts with ... end result is the man must stop potentially lifesaving ...
... Gentiva Health,Services, Inc. (Nasdaq: GTIV ), the ... announced today that it is,scheduled to present from 1:30 ... the 26th Annual JPMorgan Healthcare Conference in San Francisco., ... via a live audio web cast,which may be accessed ...
... taken more seriously , , WEDNESDAY, Dec. 26 (HealthDay News) ... person,s risk of having a stroke or developing dementia, ... to previous research linking "mini-strokes" to full-fledged strokes, make ... neurology at Johns Hopkins University School of Medicine. , ...
... feature new commercials, print ads and a new website, ... ) today announced that the Company will unveil a new ... 2008. The,focus of the campaign will be celebrity spokeswoman Genie ... just a few months on the,Medifast Program. Francis is best ...
Cached Medicine News:Health News:AHF Says 'Op-Out' Clause is Crucial to New Jersey Law Requiring HIV Testing of Pregnant Women 2Health News:AHF Says 'Op-Out' Clause is Crucial to New Jersey Law Requiring HIV Testing of Pregnant Women 3Health News:Bevacizumab found to improve survival for patients with advanced breast cancer 2Health News:Aspirin, Hormone Therapy Combo Can Shorten Lives of Prostate Cancer Patients 2Health News:Aspirin, Hormone Therapy Combo Can Shorten Lives of Prostate Cancer Patients 3Health News:Gentiva(R) Health Services to Present January 8 at JPMorgan Healthcare Conference in San Francisco 2Health News:Gentiva(R) Health Services to Present January 8 at JPMorgan Healthcare Conference in San Francisco 3Health News:Temporary Amnesia, Confusion Raise Stroke, Dementia Risk 2Health News:Temporary Amnesia, Confusion Raise Stroke, Dementia Risk 3Health News:Medifast, Inc. to Unveil New Advertising Campaign Featuring Genie Francis and New Web Features in Early 2008 2Health News:Medifast, Inc. to Unveil New Advertising Campaign Featuring Genie Francis and New Web Features in Early 2008 3Health News:Medifast, Inc. to Unveil New Advertising Campaign Featuring Genie Francis and New Web Features in Early 2008 4
... of insulin is the C-terminal cleavage product ... to the mature insulin molecule. Although the ... does undergo significant liver or extra-renal metabolism ... half-life than insulin [1]. In addition, C-peptide ...
... a 32 kDa glycoprotein secreted by the ... [1]. The structure of human TSH is ... placental gonadotropins, consisting of an a-subunit which ... and a unique beta-subunit, which confers hormonal ...
... primarily by 5-monodeioination of thyroxine (T4) in ... production occurs at a rate which is ... of T3 from the thyroid gland into ... to 80-100 micrograms/day for T4. In addition, ...
... monomeric protein produced and stored in somatotrophs ... released from the pituitary into the bloodstream ... control of hypothalamic somatostatin (SS) and GH-releasing ... of GH release appears to be regulated ...
Medicine Products: